Congress mandates pandemic testing blueprint—with private industry at the table
H.R. 1108 — Diagnostics Testing Preparedness Plan Act of 2025 · Filed by Mariannette Miller-Meeks (R-IA) · 3 cosponsors · Introduced Feb 7, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires the Secretary of Health and Human Services to develop and publicly release a plan for rapidly developing, validating, manufacturing, and distributing diagnostic tests during public health emergencies (such as pandemics or bioterrorism threats). The plan must describe processes for scaling testing capacity, identify domestic manufacturing capabilities, evaluate new testing technologies, and coordinate between government agencies, private manufacturers, laboratories, and states. The Secretary must release the plan within one year and update it every three years.
Why we flagged it
The bill's core function is to mandate development of a diagnostic testing preparedness plan for public health emergencies. It is a planning and coordination requirement, not a funding mechanism or regulatory change, and serves broad public health readiness.
What the text implies
- The bill authorizes the Secretary to contract with private entities to build domestic testing capacity, which may create long-term procurement relationships and subsidize private diagnostic manufacturers through government contracts without explicit appropriations limits.
- The plan's requirement to assess 'novel technologies and platforms' may accelerate adoption of unproven or proprietary diagnostic methods if they are included in the preparedness framework, potentially locking in vendor dependencies.
The full analysis lists 3 implications of this text.
Who stands to gain
diagnostic test manufacturers; clinical and reference laboratories; medical device companies